NAYA Therapeutics Regains Independence to Advance First-in-Class Cancer Immunotherapies with 2025-2026 Clinical Milestones
核心洞察
NAYA Therapeutics (搜索) has separated from INVO Fertility (搜索) to focus exclusively on developing first and potential best-in-class cancer immunotherapies for hepatocellular carcinoma (搜索) and multiple myeloma (搜索).
The company is targeting hepatocellular carcinoma (搜索) where 70-85% of patients are non-responders to checkpoint inhibitors, with Phase I/II trials for NY-303 expected to begin enrollment in 2025.
NAYA's pipeline includes NY-500, positioned as the first PD-1 (搜索)/VEGF (搜索) therapy to market in HCC with trials starting in 2026, and NY-338 for multiple myeloma (搜索) with a differentiated profile compared to daratumumab and T-cell engagers.
NAYA Therapeutics (搜索) has regained its status as a privately-held company following its strategic separation from INVO Fertility (搜索), positioning the clinical-stage biopharmaceutical company to focus exclusively on advancing its portfolio of first and potential best-in-class cancer immunotherapies. The separation enables NAYA to optimize its portfolio development strategy for value maximization and market attractiveness as it approaches critical clinical development milestones.
Targeting High Unmet Medical Need in Cancer
NAYA is concentrating its efforts on two priority therapeutic areas with significant unmet medical needs. In hepatocellular carcinoma (搜索) (HCC), the company is addressing a critical gap where 70-85% of candidates for systemic therapy are non-responders to checkpoint inhibitors. The second focus area is multiple myeloma (搜索), representing a large and rapidly-growing market requiring new therapies to address the limitations of existing treatments including daratumumab and T-cell engagers.
Clinical Pipeline Advancing Toward Key Milestones
The company's lead candidate NY-303 is positioned to unlock the biology of checkpoint inhibitor non-responders in HCC, with Phase I/II clinical trial enrollment expected to begin in 2025. This multifunctional antibody targeting GPC3 (搜索)/NKp46 (搜索)/CD16 (搜索) represents a unique approach to addressing treatment resistance in liver cancer.
Following NY-303, NAYA plans to initiate Phase I/II clinical trials for NY-500 in 2026, which is positioned to be the first PD-1 (搜索)/VEGF (搜索) therapy to reach the market in HCC. The company is also developing NY-338, a CD38 (搜索)/NKp46 (搜索)/CD16 (搜索) multifunctional antibody with a differentiated profile compared to current standard-of-care options, with Phase I/II trials in multiple myeloma (搜索) anticipated to commence patient enrollment in 2026.
Expanding Therapeutic Arsenal
Beyond its multifunctional antibody platform, NAYA is initiating development of a novel targeted radioimmunotherapy candidate for HCC to further strengthen its therapeutic franchise. This addition to the pipeline demonstrates the company's commitment to developing comprehensive treatment options for liver cancer patients.
Leadership Perspective on Clinical Potential
"We're incredibly excited about the clinical potential of NAYA's first and best-in-class cancer immunotherapeutics and their advancement towards near-term clinical milestones," commented Dr. Daniel Teper, NAYA's CEO. He emphasized that as the company accelerates advancement of these breakthrough therapies to market, NAYA is positioned to rapidly unlock its valuation and partnership attractiveness.
The separation from INVO Fertility (搜索) includes the formation of a new board of directors and executive team specifically focused on accelerating clinical development and corporate growth. INVO will retain a minority non-voting equity interest in NAYA following the separation, while NAYA operates as an independent entity in the rapidly-growing multifunctional antibody and radioimmunotherapy markets.